A researcher works on a vaccine against the new coronavirus COVID-19 at the Copenhagen's University research lab in Copenhagen, Denmark, on March 23, 2020.
Thibault Savary | AFP | Getty Images
(This story is only for CNBC Pro subscribers)
Six current Covid-19 vaccine candidates already demonstrate a promising combination of clinical success and an ability to be manufactured at scale, meaning the U.S. could have millions of doses as soon as this autumn, Morgan Stanley told clients.